お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:去勢抵抗性前立腺がん (CRPC) の世界市場:市場規模・シェア・動向分析、部門別予測 (治療法別 (化学療法、ホルモン療法、免疫療法、放射線療法)・地域別)
市場調査レポート
商品コード
977792

去勢抵抗性前立腺がん (CRPC) の世界市場:市場規模・シェア・動向分析、部門別予測 (治療法別 (化学療法、ホルモン療法、免疫療法、放射線療法)・地域別)

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2020 - 2027

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 90 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円
去勢抵抗性前立腺がん (CRPC) の世界市場:市場規模・シェア・動向分析、部門別予測 (治療法別 (化学療法、ホルモン療法、免疫療法、放射線療法)・地域別)
出版日: 2020年11月11日
発行: Grand View Research, Inc.
ページ情報: 英文 90 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の去勢抵抗性前立腺がん治療の市場規模は、2020~2027年に8.4%のCAGRで拡大し、2027年までに162億米ドルに達すると推定されています。治験の進展やパイプライン製品の上市といった動きが市場の成長促進につながると考えられています。

当レポートでは、世界の去勢抵抗性前立腺がん (CRPC) 治療の市場について分析し、市場の基本構造や主な促進・抑制要因、治療法別・地域別の市場動向見通し (今後8年間分)、主要企業のプロファイルと戦略展開状況、といった情報を取りまとめてお届けいたします。

目次

第1章 調査方法・範囲

第2章 エグゼクティブサマリー

第3章 去勢抵抗性前立腺がん (CRPC) 市場:変動要因・傾向・範囲

  • 市場連関構造
  • 製品普及率・成長率の見通し:マッピング
  • ユーザー視点の分析
  • 規制の枠組み
  • 市場力学
  • 去勢抵抗性前立腺がん:市場分析ツール

第4章 去勢抵抗性前立腺がん市場:治療法別の推定値と動向分析

  • 市場の定義と範囲
  • 市場シェア分析:治療法別 (最新値・予測値)
  • 治療法別ダッシュボード
  • 市場動向:治療法別 (実績値・予測値)
  • 市場規模とその予測、動向分析 (実績値・予測値)
    • 化学療法
    • ホルモン療法
    • 免疫療法
    • 放射線療法

第5章 去勢抵抗性前立腺がん市場:地域別

  • 市場シェア分析:地域別 (最新値・予測値)
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第6章 企業プロファイル

  • 主要企業と最近の動向、業界への影響
  • 主要企業の分類 (革新的企業、先駆的企業、新規企業)
  • ベンダー情勢
  • 上場会社
  • 未上場企業 (プライベートカンパニー)
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Regulatory Framework
  • TABLE 4 Global Castrate-resistant Prostate Cancer Market, By Region, 2016 - 2027 (USD Million)
  • TABLE 5 Global Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 6 North America Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 7 North America Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 9 Canada Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 10 Europe Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 11 Europe Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 12 U.K. Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 13 Germany Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 14 France Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 15 Spain Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 16 Italy Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 17 Russia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 18 Asia Pacific Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 19 Asia Pacific Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 20 China Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 21 Japan Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 22 India Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 23 South Korea Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 24 Singapore Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 25 Australia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 26 Latin America Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 27 Latin America Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 28 Brazil Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 29 Mexico Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 30 Argentina Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 31 MEA Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 32 MEA Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 33 South Africa Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 34 UAE Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 35 Saudi Arabia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Castrate-resistant Prostate Cancer Market Segmentation
  • FIG. 2 Market Research Process
  • FIG. 3 Information Procurement
  • FIG. 4 Primary Research Pattern
  • FIG. 5 Market Research Approaches
  • FIG. 6 Value-Chain-Based Sizing & Forecasting
  • FIG. 7 QFD Modeling for Market Share Assessment
  • FIG. 8 Market Formulation & Validation
  • FIG. 9 Castrate-resistant Prostate Cancer Market Snapshot
  • FIG. 10 Castrate-resistant Prostate Cancer Market Driver Impact
  • FIG. 11 Castrate-resistant Prostate Cancer Market Restraint Impact
  • FIG. 12 Penetration and Growth Prospect Mapping
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 SWOT Analysis, By Factor (Political & Legal Economic and Technological)
  • FIG. 15 Therapy Market Share Analysis, 2019 & 2027
  • FIG. 16 Therapy Dashboard
  • FIG. 17 Chemotherapy Market, 2016 - 2027 (USD Million)
  • FIG. 18 Hormonal Therapy Market, 2016 - 2027 (USD Million)
  • FIG. 19 Immunotherapy Derivatives Market, 2016 - 2027 (USD Million)
  • FIG. 20 Radiotherapy Market, 2016 - 2027 (USD Million)
  • FIG. 21 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
  • FIG. 22 North America
  • FIG. 23 North America Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 24 U.S.
  • FIG. 25 U.S. Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 26 Canada
  • FIG. 27 Canada Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 28 Europe
  • FIG. 29 Europe Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 30 U.K.
  • FIG. 31 U.K. Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 32 Germany
  • FIG. 33 Germany Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 34 France
  • FIG. 35 France Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 36 Spain
  • FIG. 37 Spain Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 38 Italy
  • FIG. 39 Italy Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 40 Russia
  • FIG. 41 Russia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 42 Asia Pacific
  • FIG. 43 Asia Pacific Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 44 Japan
  • FIG. 45 Japan Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 46 China
  • FIG. 47 China Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 48 India
  • FIG. 49 India Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 50 South Korea
  • FIG. 51 South Korea Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 52 Singapore
  • FIG. 53 Singapore Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 54 Australia
  • FIG. 55 Australia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 56 Latin America
  • FIG. 57 Latin America Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 58 Brazil
  • FIG. 59 Brazil Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 60 Mexico
  • FIG. 61 Mexico Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 62 Argentina
  • FIG. 63 Argentina Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 64 Middle East & Africa
  • FIG. 65 Middle East & Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 66 South Africa
  • FIG. 67 South Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 68 UAE
  • FIG. 69 UAE Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 70 Saudi Arabia
  • FIG. 71 Saudi Arabia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 72 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • FIG. 73 Competitive Dashboard Analysis
  • FIG. 74 Market Differentiators
目次
Product Code: GVR-4-68039-237-3

Castrate-resistant Prostate Cancer Market Growth & Trends:

The global castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the market and held the largest revenue share of 83.1% in 2019. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights:

  • Prostate cancer is the highest prevalent cancer in men. 1 in 9 men are diagnosed with prostate cancer
  • Within 3 years of diagnosis, 10-50% of overall prostate cancer cases develop into metastatic castrate-resistant prostate cancer
  • The recommendation of products from healthcare authorities is expected to increase the sales of the drug, thereby fueling the market growth. For instance, Provenge is recommended by the Society for Immunotherapy of Cancer, the National Comprehensive Cancer Network, and the American Urological Association
  • Australia and New Zealand have the highest prevalence rate of the disease, followed by North America and Europe
  • In Asia Pacific, the market is likely to witness the fastest CAGR of 11.5% from 2020 to 2027

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third-party perspectives
    • 1.3.4. Primary research
  • 1.4. Information Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
  • 1.8. Commodity Flow Analysis
  • 1.9. Approach: Commodity Flow Approach
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Objective
  • 1.13. Objective 1
  • 1.14. Objective 2
  • 1.15. Objective 3
  • 1.16. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Castrate-Resistant Prostate Cancer Market Variables, Trends & Scope

  • 3.1. Castrate-Resistant Prostate Cancer Market Lineage outlook
    • 3.1.1. Parent market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. User Perspective Analysis
  • 3.4. Regulatory Framework
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising prevalence of castrate-resistant prostate cancer
      • 3.5.1.2. Increasing technological advancements
      • 3.5.1.3. Rising adoption of treatment
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. Lack of standard therapy
  • 3.6. Castrate-Resistant Prostate Cancer Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat from New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTEL Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Environmental Landscape
      • 3.6.2.3. Social Landscape
      • 3.6.2.4. Technology Landscape
      • 3.6.2.5. Legal Landscape

Chapter 4. Castrate-Resistant Prostate Cancer Market: Therapy Estimates & Trend Analysis

  • 4.1. Definitions & Scope
  • 4.2. Therapy Market Share Analysis, 2019 & 2027
  • 4.3. Therapy Dashboard
  • 4.4. Castrate-Resistant Prostate Cancer Market, By Therapy, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 4.5.1. Chemotherapy
      • 4.5.1.1. Chemotherapy market, 2016 - 2027 (USD Million)
    • 4.5.2. Hormonal Therapy
      • 4.5.2.1. Hormonal therapy market, 2016 - 2027 (USD Million)
    • 4.5.3. Immunotherapy
      • 4.5.3.1. Immunotherapy market, 2016 - 2027 (USD Million)
    • 4.5.4. Radiotherapy
      • 4.5.4.1. Radiotherapy market, 2016 - 2027 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Segment Analysis, By Region, 2016 - 2027 (USD Million)

  • 5.1 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
    • 5.1.1 North America
      • 5.1.1.1 North America market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.1.2 U.S.
      • 5.1.1.2.1 U.S. market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.1.3 Canada
      • 5.1.1.3.1 Canada market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.2 Europe
      • 5.1.2.1 Europe market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.2 U.K.
      • 5.1.2.2.1 U.K. market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.3 Germany
      • 5.1.2.3.1 Germany market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.4 France
      • 5.1.2.4.1 France market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.5 Spain
      • 5.1.2.5.1 Spain market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.6 Italy
      • 5.1.2.6.1 Italy market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.7 Russia
      • 5.1.2.7.1 Russia market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.3 Asia Pacific
      • 5.1.3.1 Asia Pacific market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.2 Japan
      • 5.1.3.2.1 Japan market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.3 China
      • 5.1.3.3.1 China market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.4 India
      • 5.1.3.4.1 India market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.5 South Korea
      • 5.1.3.5.1 South Korea market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.6 Singapore
      • 5.1.3.6.1 Singapore market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.7 Australia
      • 5.1.3.7.1 Australia market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.4 Latin America
      • 5.1.4.1 Latin America market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.2 Brazil
      • 5.1.4.2.1 Brazil market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.3 Mexico
      • 5.1.4.3.1 Mexico market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.4 Argentina
      • 5.1.4.4.1 Argentina market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.6 Middle East and Africa
      • 5.1.6.1 Middle East & Africa market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.2 South Africa
      • 5.1.6.2.1 South Africa market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.3 UAE
      • 5.1.6.3.1 UAE market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.4 Saudi Arabia
      • 5.1.6.4.1 Saudi Arabia market estimates and forecast, 2015 - 2027 (USD Million)

Chapter 6. Company Profiles

  • 6.1. Recent developments & impact analysis, by key market participants
  • 6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 6.3. Public Companies
    • 6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 6.3.2. Competitive dashboard analysis
    • 6.3.3. Market differentiators
  • 6.4. Private Companies
  • 6.5. Company Profiles
    • 6.5.1. Sanofi
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Johnson & Johnson Services Inc.
      • 6.5.2.1. Company Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Pfizer Inc.
      • 6.5.3.1. Company Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Astellas Pharma, Inc.
      • 6.5.4.1. Company Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Bayer AG
      • 6.5.5.1. Company Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.